Calliditas Therapeutics Stock Buy Hold or Sell Recommendation
| CALT Stock | USD 20.33 0.23 1.12% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Calliditas Therapeutics is 'Cautious Hold'. Macroaxis provides Calliditas Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CALT positions. The advice algorithm takes into account all of Calliditas Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Calliditas Therapeutics' buy or sell advice are summarized below:
Real Value 28.21 | Target Price 51.8 | Hype Value 20.33 | Market Value 20.33 | Naive Value 21.49 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Calliditas Therapeutics given historical horizon and risk tolerance towards Calliditas Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Calliditas Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Calliditas |
Execute Calliditas Therapeutics Buy or Sell Advice
The Calliditas recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Calliditas Therapeutics. Macroaxis does not own or have any residual interests in Calliditas Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Calliditas Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Calliditas Therapeutics Trading Alerts and Improvement Suggestions
| Calliditas Therapeutics generated a negative expected return over the last 90 days | |
| Calliditas Therapeutics has high historical volatility and very poor performance | |
| Calliditas Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.21 B. Net Loss for the year was (466.19 M) with profit before overhead, payroll, taxes, and interest of 787.68 M. | |
| Calliditas Therapeutics generates negative cash flow from operations | |
| Latest headline from seekingalpha.com: Calliditas releases phase 2 results on head and neck cancer asset setanaxib |
Calliditas Therapeutics Returns Distribution Density
The distribution of Calliditas Therapeutics' historical returns is an attempt to chart the uncertainty of Calliditas Therapeutics' future price movements. The chart of the probability distribution of Calliditas Therapeutics daily returns describes the distribution of returns around its average expected value. We use Calliditas Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Calliditas Therapeutics returns is essential to provide solid investment advice for Calliditas Therapeutics.
| Mean Return | -0.03 | Value At Risk | -4.76 | Potential Upside | 5.95 | Standard Deviation | 3.39 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Calliditas Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Calliditas Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Calliditas Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Calliditas Therapeutics backward and forwards among themselves. Calliditas Therapeutics' institutional investor refers to the entity that pools money to purchase Calliditas Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 602 | Simplex Trading, Llc | 2023-12-31 | 324 | Bank Of America Corp | 2023-12-31 | 313 | Rhumbline Advisers | 2023-12-31 | 164 | Colonial Asset Management Inc | 2023-12-31 | 105 | Cutler Group Lp | 2023-12-31 | 100.0 | Qube Research & Technologies | 2023-12-31 | 72.0 | Missouri Trust & Investment Co | 2023-12-31 | 35.0 | Nalls Sherbakoff Group, Llc | 2023-09-30 | 35.0 | Bvf Inc | 2023-09-30 | 750 K | Deutsche Bank Ag | 2023-12-31 | 50.5 K |
Calliditas Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 97.4M | 242.8M | (40.8M) | 293.6M | (275.4M) | (261.6M) | |
| Free Cash Flow | (87.2M) | (309.2M) | (484.2M) | (313.9M) | (447.4M) | (425.1M) | |
| Depreciation | 1.8M | 2.8M | 34.4M | 12.9M | 16.6M | 8.4M | |
| Other Non Cash Items | 62K | (4K) | 66.7M | (26.5M) | 207.6M | 218.0M | |
| Net Income | (28.0M) | (379.7M) | (524.5M) | (421.9M) | (466.2M) | (442.9M) | |
| End Period Cash Flow | 753.5M | 996.3M | 955.5M | 1.2B | 973.7M | 694.4M | |
| Investments | (18.1M) | (172.6M) | (24.3M) | (5.1M) | (12.9M) | (13.5M) | |
| Net Borrowings | (1.7M) | (4.0M) | 193.9M | 482.1M | 554.4M | 582.2M | |
| Change To Netincome | 5.6M | 70.2M | 33.2M | 12.5M | 14.4M | 19.6M |
Calliditas Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Calliditas Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Calliditas Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Calliditas stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.09 | |
β | Beta against NYSE Composite | 0.71 | |
σ | Overall volatility | 3.47 | |
Ir | Information ratio | -0.03 |
Calliditas Therapeutics Volatility Alert
Calliditas Therapeutics exhibits very low volatility with skewness of 0.33 and kurtosis of -0.13. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Calliditas Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Calliditas Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Calliditas Therapeutics Fundamentals Vs Peers
Comparing Calliditas Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Calliditas Therapeutics' direct or indirect competition across all of the common fundamentals between Calliditas Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Calliditas Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Calliditas Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Calliditas Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Calliditas Therapeutics to competition |
| Fundamentals | Calliditas Therapeutics | Peer Average |
| Return On Equity | -0.85 | -0.31 |
| Return On Asset | -0.13 | -0.14 |
| Profit Margin | (0.39) % | (1.27) % |
| Operating Margin | 0.05 % | (5.51) % |
| Current Valuation | 1.11 B | 16.62 B |
| Shares Outstanding | 26.84 M | 571.82 M |
| Shares Owned By Institutions | 2.86 % | 39.21 % |
| Number Of Shares Shorted | 7.11 K | 4.71 M |
| Price To Book | 16.34 X | 9.51 X |
| Price To Sales | 0.45 X | 11.42 X |
| Revenue | 1.21 B | 9.43 B |
| Gross Profit | 787.68 M | 27.38 B |
| EBITDA | (367.8 M) | 3.9 B |
| Net Income | (466.19 M) | 570.98 M |
| Total Debt | 979.13 M | 5.32 B |
| Debt To Equity | 0.66 % | 48.70 % |
| Current Ratio | 5.32 X | 2.16 X |
| Cash Flow From Operations | (434.65 M) | 971.22 M |
| Short Ratio | 1.31 X | 4.00 X |
| Earnings Per Share | (1.61) X | 3.12 X |
| Target Price | 41.76 | |
| Number Of Employees | 217 | 18.84 K |
| Beta | 1.4 | -0.15 |
| Market Capitalization | 552.82 M | 19.03 B |
| Total Asset | 1.9 B | 29.47 B |
| Retained Earnings | (2.31 B) | 9.33 B |
| Working Capital | 868.01 M | 1.48 B |
| Net Asset | 1.9 B |
Calliditas Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Calliditas . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 20.33 | |||
| Day Typical Price | 20.33 | |||
| Price Action Indicator | (0.12) | |||
| Period Momentum Indicator | (0.23) | |||
| Relative Strength Index | 47.46 |
About Calliditas Therapeutics Buy or Sell Advice
When is the right time to buy or sell Calliditas Therapeutics? Buying financial instruments such as Calliditas Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 13.9M | 18.0M | 287.9M | 302.3M | Total Assets | 1.5B | 2.0B | 1.9B | 1.0B |
Use Investing Ideas to Build Portfolios
In addition to having Calliditas Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alternative Energy Thematic Idea Now
Alternative Energy
Large and mid-size companies, ETFs and funds that are either investing or directly involved in providing energy derived from sources not connected to fossil fuels, do not consume natural resources, and do not harm the environment. This includes wind power, nuclear and solar energy, biofuel, ethanol, hydrogen and others alternative sources of energy. The Alternative Energy theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Energy Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Calliditas Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Calliditas Stock analysis
When running Calliditas Therapeutics' price analysis, check to measure Calliditas Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calliditas Therapeutics is operating at the current time. Most of Calliditas Therapeutics' value examination focuses on studying past and present price action to predict the probability of Calliditas Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calliditas Therapeutics' price. Additionally, you may evaluate how the addition of Calliditas Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Calliditas Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calliditas Therapeutics. If investors know Calliditas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calliditas Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.61) | Revenue Per Share 44.972 | Quarterly Revenue Growth 0.052 | Return On Assets (0.13) | Return On Equity (0.85) |
The market value of Calliditas Therapeutics is measured differently than its book value, which is the value of Calliditas that is recorded on the company's balance sheet. Investors also form their own opinion of Calliditas Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calliditas Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calliditas Therapeutics' market value can be influenced by many factors that don't directly affect Calliditas Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Calliditas Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calliditas Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calliditas Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.